ImmuCell Corporation (ICCC)

Market Cap	47.59M
Revenue (ttm)	23.84M
Net Income (ttm)	-3.81M
Shares Out	8.91M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,970
Open	4.84
Previous Close	4.96
Day's Range	4.75 - 5.34
52-Week Range	3.34 - 5.82
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2025

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides Califor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 1987
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCC
• Website: https://immucell.com

Financial Performance

In 2023, ImmuCell's revenue was $17.47 million, a decrease of -5.90% compared to the previous year's $18.57 million. Losses were -$5.77 million, 131.6% more than in 2022.